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Kinases are often aberrantly activated in various 
tumor types by overexpression, point mutations, 
chromosomal translocations and other mechanisms. 
Therefore, small molecule inhibitors that block the 
enzymatic activity of kinases have been developed for 
different targets and are successfully used for the treatment 
of cancer patients. A major drawback of these molecularly 
targeted therapies is the frequent development of therapy 
resistance, often caused by point mutations in the target 
protein ([1]). This can manifest in short-lived remissions 
and disease progression. A valuable strategy to counteract 
these developments is the identification and subsequent 
targeting of additional sites on the oncogenic driver kinase. 
To qualify as an allosteric drug target, these regulatory 
sites need to be essential for the oncogenic activity of 
the respective kinase. Alternatively, they may represent 
allosteric attenuators of enzymatic activity, critical 
protein-protein interactions or downstream signaling 
pathways. In the past years, several such sites were 
identified in hallmark kinases. For example, it was shown 
that the activation of the epidermal growth factor receptor 
(EGFR) results from the formation of an asymmetric 
dimer in which the C-terminal lobe of one kinase domain 
binds to the N-terminal lobe of the other kinase domain 
and allosterically activates it. The site of interaction and 
mechanism of kinase activation is reminiscent to that 
of cyclins in activated cyclin-dependent kinase/cyclin 
complexes [2]. Also, the activation of the BRAF kinase, 
which is frequently mutated in tumors depends on the 
formation of side-to-side homo- and hetero-dimers with 
CRAF or the pseudo-kinase kinase suppresor of Ras 
(KSR) [3]. Paradoxically, inhibition of BRAF kinase 
activity by mutation or certain BRAF kinase inhibitors 
resulted in activation of the MEK-ERK pathway [3].
The hallmark of chronic myeloid leukemia (CML) 
is the expression of the oncogenic kinase Bcr-Abl, which 
arises from the Philadelphia chromosome translocation 
[4]. Bcr-Abl’s high activity is targeted by the ATP-
competitive tyrosine kinase inhibitor Gleevec leading to 
durable remissions in CML patients [4].
Recently, the myristate binding pocket in the 
C-terminal lobe of the Abl kinase domain was identified 
as a site for allosteric regulation of Bcr-Abl activity [5]. 
A small molecule that was engineered to bind to the 
myristate binding pocket was shown to inhibit Bcr-Abl 
allosterically [6].
In addition, Bcr-Abl as well as its proto-oncogenic 
constituent c-Abl (ABL1) have a Src homology 2 (SH2) 
domain N-terminal to their tyrosine kinase domains - a 
conserved feature among the class of cytoplasmic tyrosine 
kinases. The analysis of active Abl conformations lead 
to the finding that SH2 domains are positive allosteric 
effectors in cytoplasmic tyrosine kinases via the formation 
of an intramolecular interface of the SH2 domain with the 
kinase domain [7]. The SH2-kinase domain interaction 
in Bcr-Abl was both necessary and sufficient for high 
catalytic activity of the enzyme. Disruption of this 
interface led to inhibition of downstream events critical 
for CML signaling and, importantly, completely abolished 
leukemia formation in mice [8]. Furthermore, disruption of 
the SH2-kinase interface increased sensitivity of imatinib-
resistant Bcr-Abl mutants to TKI inhibition. To target this 
interaction, an engineered Abl SH2 binding fibronectin 
type III-monobody was developed that inhibited Bcr-Abl 
kinase activity inducing apoptosis of primary CML cells. 
This validated the SH2-kinase interface as an allosteric 
target for therapeutic intervention [8].
The exquisite affinity and specificity of monobodies 
exemplifies its general utility as target validation tools 
for preclinical studies. On the other hand, the necessity 
for intracellular delivery that may only be achieved 
using lentiviral gene transfer or fusion of the monobody 
to membrane-permeable peptides will likely limit or 
preclude the use of monobodies as drug-like molecules in 
clinical applications. 
In contrast, small-molecule protein-protein 
interaction inhibitors have been developed for a number 
of protein targets, breaking with the dogma that protein-
protein interfaces are ‘undruggable’. However, interfering 
with intramolecular domain interactions (like the SH2-
kinase interface in Bcr-Abl) might require very high local 
concentrations of inhibitor that may be difficult to achieve 
using intracellular delivery of proteins or peptides. 
Therefore, we believe that the development of a small-
molecule inhibitor of the SH2-kinase domain interface 
that may be used in combination with approved Bcr-Abl 
tyrosine kinase inhibitors could be feasible.
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